Summit Therapeutics 株価情報 (NASDAQ: SMMT)

最新ニュース Summit Therapeutics (NASDAQ:SMMT) 株価情報

Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics Inc

These monthly dividends, which will be payable pursuant to the table below, total $0.75 per share for the first quarter of 2025 and represent a 2.0% increase from the regular monthly dividends declared for the fourth quarter of 2024 and a 4.2% increase from the regular monthly dividends paid in the first quarter of 2024.

News

Dividends

MAIN

Main Street Declares Supplemental Dividend Of $0.30 Per Share Payable In December 2024; Boosts Regular Monthly Dividends To $0.25 Per Share For Each Of January, February And March 2025

CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.51 by 29.41 percent. This is a 100 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $124.75 million which beat the analyst consensus estimate of $117.13 million by 6.51 percent. This is a 17.84 percent increase over sales of $105.86 million the same period last year.

Earnings

Earnings Beats

PMTS

CPI Card Q3 Adj $0.66 Beats $0.51 Estimate, Sales $124.75M Beat $117.13M Estimate

2024 Outlook:
Based on its current forecast, Cummins is maintaining its full-year 2024 revenue guidance to be in the range of down 3% to flat. EBITDA is expected to be approximately 15.5%; at the top end of the previous guidance of 15.0% to 15.5%.
Cummins plans to continue generating strong operating cash flow and returns for shareholders and is committed to our long-term strategic goal of returning 50% of operating cash flow back to shareholders. In the near term, we will focus on reinvesting for profitable growth, dividends and reducing debt.

Guidance

Cummins Affirms FY24 Sales Guidance Of $33.04B-$34.06B Vs, $33.60B Estimate

2024 guidance is as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$950 million - $960 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Transaction costs</td>
<td colspan="1" rowspan="1">~16.0% of revenue</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$255 million to $265 million</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

PAYO

Payoneer Global Sees FY24 Revenue $950M-$960M (Prior $920M-$930M) Vs $928.71M Est.; Transaction Costs ~16.0% Of Revenue (Prior ~16.5%); Adjusted EBITDA $255M-$265M (Prior $225M-$235M)

2024&nbsp;Financial Outlook
Based on its current operating plans, Karyopharm has further narrowed its guidance for full year 2024 as follows:
<ul>
<li>Total revenue to be in the range of $145.0 million to $155.0 million as compared to the Company's prior guidance of $145.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.</li>
<li>U.S. XPOVIO net product revenue to be in the range of $110.0 million to $115.0 million as compared to the Company's prior guidance of $105.0 million to $120.0 million.</li>
<li>R&amp;D and selling, general and administrative (SG&amp;A) expenses to be in the range of $255.0 million to $265.0 million, which includes approximately $20.0 million estimated non-cash stock-based compensation expense, as compared to the Company's prior guidance of $250.0 million to $265.0 million.</li>
<li>The Company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its license agreements and ongoing disciplined expense management and cost saving measures, will be sufficient to fund its planned operations into the first quarter of 2026.</li>
</ul>

Biotech

Health Care

General

KPTI

Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Baird analyst Tristan Gerra maintains Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) with a Outperform and lowers the price target from $7 to $5.

Price Target

Analyst Ratings

NVTS

Baird Maintains Outperform on Navitas Semiconductor, Lowers Price Target to $5

LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.54 by 16.14 percent. The company reported quarterly sales of $651.854 million which beat the analyst consensus estimate of $646.459 million by 0.83 percent. This is a 5.56 percent increase over sales of $617.539 million the same period last year.

LGIH

LGI Homes Q3 2024 GAAP EPS $2.95 Beats $2.54 Estimate, Sales $651.854M Beat $646.459M Estimate

Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is currently under investigation for potential tax fraud in France and the Netherlands. 
What Happened: The offices of the streaming giant were searched by investigators on Tuesday morning as part of a preliminary inquiry into alleged tax fraud and money laundering, reported Reuters.
The investigation, led by the French National Financial Prosecutor&#8217;s Office (PNF,) is focused on potential financial crimes and corruption. The probe, which began in November 2022, has led to searches at Netflix&#8217;s offices in central Paris and its European headquarters in Amsterdam.
A preliminary investigation in France does not automatically indicate that criminal charges will be filed or that a trial will occur.
See Also: <a href="https://www.benzinga.com/news/24/11/41703723/mark-cubans-million-dollar-advice-to-teens-if-i-were-16-again-id-start-this-lucrative-side-hustle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban&#8217;s Million-Dollar Advice To Teens: &#8216;If I Were 16 Again, I&#8217;d Start This Lucrative Side Hustle&#8217;</a>
Dutch authorities were simultaneously searching Netflix&#8217;s European headquarters in Amsterdam, according to the French judicial source. Neither Netflix France nor Netflix Netherlands have released a statement.
Netflix did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: In 2022, Netflix settled a tax dispute with Italy by paying 55.8 million euros ($60.78 million). The company, which opened its Paris office in 2020, produces most of its original films and series by working with third-party contractors.
This investigation comes at a time of significant change within Netflix. The company recently <a href="https://www.benzinga.com/news/24/10/41631621/netflix-restructures-leadership-bids-farewell-to-two-key-executives">restructured its leadership</a>, with the departure of two key executives, Rachel Whetstone, chief communications officer, and Dean Garfield, VP of public policy. This restructuring was part of a planned change announced by Co-CEO Ted Sarandos.
Price Action: Netflix stock, which has gained 61.26% so far this year, was down 0.2% during premarket trading on Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41701405/dont-ever-use-this-word-around-mark-cuban-you-sound-stupid-because-youre-trying-to-sound-smart?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Don&#8217;t Ever Use This Word Around Mark Cuban: &#8216;You Sound Stupid &#8230; Because You&#8217;re Trying To Sound Smart&#8217;</a></li>
</ul>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Entertainment

Equities

Global

Markets

Tech

NFLX

Netflix In Hot Water As Tax Fraud Investigators Raid French, Dutch Offices: Report

CRGO

Freightos Welcomes Qantas Freight To WebCargo Platform, Enhancing Digital Booking Options Across Key Trans-Pacific Trade Routes

Keybanc analyst John Vinh maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Overweight and lowers the price target from $150 to $115.

SLAB

Keybanc Maintains Overweight on Silicon Laboratories, Lowers Price Target to $115

Hillman Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. The company reported quarterly sales of $393.300 million which beat the analyst consensus estimate of $387.780 million by 1.42 percent. This is a 1.41 percent decrease over sales of $398.943 million the same period last year.

HLMN

Hillman Solutions Q3 2024 Adj. EPS $0.16, Inline, Sales $393.300M Beat $387.780M Estimate

LIND

Lindblad Expeditions Continues To See FY24 Tour Revenues Of $610M - $630M (Est $622.65M), Adjusted EBITDA  Of $88M - $98M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 13.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $38.78 million which beat the analyst consensus estimate of $37.79 million by 2.63 percent. This is a 7.70 percent increase over sales of $36.01 million the same period last year.

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) reported quarterly earnings of $5.86 per share which beat the analyst consensus estimate of $4.78 by 22.59 percent. This is a 27.67 percent increase over earnings of $4.59 per share from the same period last year. The company reported quarterly sales of $8.456 billion which beat the analyst consensus estimate of $8.294 billion by 1.96 percent. This is a 0.30 percent increase over sales of $8.431 billion the same period last year.

Cummins Q3 2024 GAAP EPS $5.86 Beats $4.78 Estimate, Sales $8.456B Beat $8.294B Estimate

Loop Capital analyst Rick Paterson downgrades Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from Buy to Hold and raises the price target from $22 to $22.5.

Downgrades

ATSG

Loop Capital Downgrades Air Transport Services Gr to Hold, Raises Price Target to $22.5

Payoneer Global Q3 2024 GAAP EPS $0.11 Beats $0.04 Estimate, Sales $248.274M Beat $225.476M Estimate

The FDA Has Extended The Target Action Date Of Its Review Of Organon's Supplemental New Drug Application For Vtama (Tapinarof) Cream, 1% For Atopic Dermatitis In Adults And Children Two Years Of Age And Older. The New Target Date Is March 12, 2025, Revised From The Original Target Action Date Of December 12

Baird analyst Tristan Gerra maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Outperform and lowers the price target from $70 to $44.

LSCC

Baird Maintains Outperform on Lattice Semiconductor, Lowers Price Target to $44

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58407d80aae83900016b3bd0/bryan-keane">Deutsche Bank analyst Bryan Keane</a> downgraded the rating for Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. <a href="https://www.benzinga.com/quote/CGNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. <a href="https://www.benzinga.com/quote/SANA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero</a> downgraded Neumora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. <a href="https://www.benzinga.com/quote/NMRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. <a href="https://www.benzinga.com/quote/IDYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CGNX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png" alt="" class="wp-image-630098" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27.png 1272w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

CGNX

IDYA

NMRA

SANA

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Keybanc analyst John Vinh maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Overweight and lowers the price target from $60 to $54.

Keybanc Maintains Overweight on Lattice Semiconductor, Lowers Price Target to $54

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

BioNTech and Moderna: A tale of two mRNA developers

Summit Therapeutics Q3 2024 Earnings Preview

Summit Therapeutics Non-GAAP EPS of -$0.05

"With the recent financing in September 2024 providing us $235M we have strengthened our cash balance to extend our cash runway" said Manmeet S. So...

Summit Therapeutics reports Q3 EPS (5c), consensus (7c)

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

Summit Therapeutics PLC ( ($SMMT) ) has realeased its Q3 earnings. Here is a breakdown of the information Summit Therapeutics PLC presented to its ...

Summit Therapeutics Advances NSCLC Trials and Strengthens Financials

H.C. Wainwright lowered the firm's price target on Summit Therapeutics (SMMT) to $44 from $45 and keeps a Buy rating on the shares following the Q3...

Summit Therapeutics price target lowered to $44 from $45 at H.C. Wainwright

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Summit Therapeutics (SMMT – Research Report), with a pri...

Summit Therapeutics (SMMT) Gets a Buy from Stifel Nicolaus

JMP Securities initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $32 price target The firm acknowledges the risk assoc...

Summit Therapeutics initiated with an Outperform at JMP Securities

BNTX

MRNA

SMMT

Press Releases

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit's Meteoric Rise: Silexion, Nuvectis, Scorpian

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Comments

Summit Therapeutics

ニュース

最新ニュース Summit Therapeutics (NASDAQ:SMMT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル